Illicit anabolic-androgenic steroid use

Hormones and Behavior

Volumn 58, Issue 1, 2010, Pages 111-121

  Kanayama, Gen ^a   Hudson, James I ^a   Pope, Harrison G ^a  

^a MCLEAN HOSPITAL   (United States)

Author keywords

Anabolic steroids; Androgen; Behavioral effects; Male; Substance dependence

Indexed keywords

ANABOLIC AGENT; ANDROGEN; ILLICIT DRUG; MONOAMINE OXIDASE INHIBITOR; OPIATE; PLACEBO; TESTOSTERONE DERIVATIVE; TRICYCLIC ANTIDEPRESSANT AGENT; STEROID;

AGGRESSION; ARTICLE; ATHLETE; ATHLETIC PERFORMANCE; BODY IMAGE; CARDIOTOXICITY; DEPRESSION; DRUG ABUSE; DRUG DEPENDENCE; ELECTROCONVULSIVE THERAPY; FATIGUE; HUMAN; HYPOGONADISM; HYPOMANIA; IMMUNOPATHOLOGY; LIVER TOXICITY; MANIA; MASCULINITY; MENOPAUSAL SYNDROME; MOOD DISORDER; MUSCULOSKELETAL DISEASE; NEPHROTOXICITY; NONHUMAN; OPIATE ADDICTION; PERSONAL APPEARANCE; PHYSICAL PERFORMANCE; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; SEXUAL DYSFUNCTION; VIOLENCE; WASTING SYNDROME; ANIMAL; PATHOPHYSIOLOGY; SUBSTANCE-RELATED DISORDERS;

ANABOLIC AGENTS; ANIMALS; HUMANS; STEROIDS; SUBSTANCE-RELATED DISORDERS;

EID: 77953480632     PISSN: 0018506X     EISSN: 10956867     Source Type: Journal    
DOI: 10.1016/j.yhbeh.2009.09.006     Document Type: Article

References (253)

1. Alexander G.M., Packard M.G., Hines M. Testosterone has rewarding affective properties in male rats: implications for the biological basis of sexual motivation. Behav. Neurosci. 1994, 108:424-428.
2. Allnutt S., Chaimowitz G. Anabolic steroid withdrawal depression: a case report. Can. J. Psychiatry 1994, 39:317-318.
3. Altschule M.D., Tillotson K.J. The use of testosterone in the treatment of depressions. N. Engl. J. Med. 1948, 239:1036-1038.
4. Diagnostic and Statistical Manual of Mental Disorders 1987, American Psychiatric Association, Revised. American Psychiatric Association, Washington, DC. Third Edition.
5. Diagnostic and statistical manual of mental disorders 1994, American Psychiatric Association, (DSM-IV). American Psychiatric Association, Washington, DC. fourth edition.
6. Annitto W.J., Layman W.A. Anabolic steroids and acute schizophrenic episode. J. Clin. Psychiatry 1980, 41:143-144.
7. Arnedo M.T., Salvador A., Martinez-Sanchis S., Gonzalez-Bono E. Rewarding properties of testosterone in intact male mice: a pilot study. Pharmacol. Biochem. Behav. 2000, 65:327-332.
8. Arvary D., Pope H.G. Anabolic-androgenic steroids as a gateway to opioid dependence. N. Engl. J. Med. 2000, 342:1532.
9. Bagatell C.J., Heiman J.R., Matsumoto A.M., Rivier J.E., Bremner W.J. Metabolic and behavioral effects of high-dose, exogenous testosterone in healthy men. J. Clin. Endocrinol. Metab. 1994, 79:561-567.
10. Bagia S., Hewitt P.M., Morris D.L. Anabolic steroid-induced hepatic adenomas with spontaneous haemorrhage in a bodybuilder. Aust. N. Z. J. Surg. 2000, 70:686-687.
11. Bahrke M.S., Yesalis C.E. Weight training. A potential confounding factor in examining the psychological and behavioural effects of anabolic-androgenic steroids. Sports Med. 1994, 18:309-318.
12. Bahrke M.S., Wright J.E., Strauss R.H., Catlin D.H. Psychological moods and subjectively perceived behavioral and somatic changes accompanying anabolic-androgenic steroid use. Am. J. Sports Med. 1992, 20:717-724.
13. Bahrke M.S., Yesalis C.E., Wright J.E. Psychological and behavioural effects of endogenous testosterone and anabolic-androgenic steroids. An update. Sports Med. 1996, 22:367-390.
14. Bahrke M.S., Yesalis C.E., Kopstein A.N., Stephens J.A. Risk factors associated with anabolic-androgenic steroid use among adolescents. Sports Med. 2000, 29:397-405.
15. Barahal H. Testosterone in male involutional melancholia: preliminary report. Psychiatr. Q. 1938, 12:743-749.
16. Basaria S., Wahlstrom J.T., Dobs A.S. Clinical review 138: anabolic-androgenic steroid therapy in the treatment of chronic diseases. J. Clin. Endocrinol. Metab. 2001, 86:5108-5117.
17. Bhasin S., Storer T.W., Berman N., Callegari C., Clevenger B., Phillips J., Bunnell T.J., Tricker R., Shirazi A., Casaburi R. The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. N. Engl. J. Med. 1996, 335:1-7.
18. Birgner C., Kindlundh-Hogberg A.M., Alsio J., Lindblom J., Schioth H.B., Bergstrom L. The anabolic androgenic steroid nandrolone decanoate affects mRNA expression of dopaminergic but not serotonergic receptors. Brain Res. 2008, 1240:221-228.
19. Björkqvist K., Nygren T., Björklund A.C., Björkqvist S.E. Testosterone intake and aggressiveness: real effect or anticipation?. Aggress. Behav. 1994, 20:17-26.
20. Boyadjiev N.P., Georgieva K.N., Massaldjieva R.I., Gueorguiev S.I. Reversible hypogonadism and azoospermia as a result of anabolic-androgenic steroid use in a bodybuilder with personality disorder. A case report. J. Sports Med. Phys. Fitness 2000, 40:271-274.
21. Brower K.J. Withdrawal from anabolic steroids. Curr. Ther. Endocrinol. Metab. 1997, 6:338-343.
22. Brower K.J. Anabolic steroid abuse and dependence. Curr. Psychiatry Rep. 2002, 4:377-387.
23. Brower K.J., Blow F.C., Beresford T.P., Fuelling C. Anabolic-androgenic steroid dependence. J. Clin. Psychiatry 1989, 50:31-33.
24. Brower K.J., Blow F.C., Eliopulos G.A., Beresford T.P. Anabolic androgenic steroids and suicide. Am. J. Psychiatry 1989, 146:1075.
25. Brower K.J., Eliopulos G.A., Blow F.C., Catlin D.H., Beresford T.P. Evidence for physical and psychological dependence on anabolic androgenic steroids in eight weight lifters. Am. J. Psychiatry 1990, 147:510-512.
26. Brower K.J., Blow F.C., Young J.P., Hill E.M. Symptoms and correlates of anabolic-androgenic steroid dependence. Br. J. Addict. 1991, 86:759-768.
27. Brown-Séquard C. Des effets produits chez l'homme par des injections souscutanées d'un liquide retiré des testicules frais de cobaye et de chien. C. R. Séance Soc. Biol. 1889, 415-422. and 429-431.
28. Bryden A.A., Rothwell P.J., O'Reilly P.H. Anabolic steroid abuse and renal-cell carcinoma. Lancet 1995, 346:1306-1307.
29. Buckley W.E., Yesalis C.E., Friedl K.E., Anderson W.A., Streit A.L., Wright J.E. Estimated prevalence of anabolic steroid use among male high school seniors. JAMA 1988, 260:3441-3445.
30. Cafri G., Thompson J.K., Ricciardelli L., McCabe M., Smolak L., Yesalis C. Pursuit of the muscular ideal: physical and psychological consequences and putative risk factors. Clin. Psychol. Rev. 2005, 25:215-239.
31. Casner S.W., Early R.G., Carlson B.R. Anabolic steroid effects on body composition in normal young men. J. Sports Med. Phys. Fitness 1971, 11:98-103.
32. Celerier E., Ahdepil T., Wikander H., Berrendero F., Nyberg F., Maldonado R. Influence of the anabolic-androgenic steroid nandrolone on cannabinoid dependence. Neuropharmacology 2006, 50:788-806.
33. Centers for Disease Control and Prevention (CDC), 2004. Youth risk behavior surveillance - United States, 2003. Morbidity and Mortality Weekly Report. 53 (SS-2), Available online at ; accessed September 6, 2009. http://www.cdc.gov/mmwr/PDF/SS/SS5302.pdf.
34. Centers for Disease Control and Prevention (CDC), 2008. Youth risk behavior surveillance - United States, 2007. Morbidity and Mortality Weekly Report. 57 (SS-4), Available online at ; accessed September 6, 2009. http://www.cdc.gov/HealthyYouth/yrbs/pdf/yrbss07_mmwr.pdf.
35. Choi P.Y., Pope H.G. Violence toward women and illicit androgenic-anabolic steroid use. Ann. Clin. Psychiatry 1994, 6:21-25.
36. Choi P.Y., Parrott A.C., Cowan D. High-dose anabolic steroids in strength athletes: effects upon hostility and aggression. Hum. Psychopharmacol. 1990, 5:349-356.
37. Clark A.S., Henderson L.P. Behavioral and physiological responses to anabolic-androgenic steroids. Neurosci. Biobehav. Rev. 2003, 27:413-436.
38. Clark B.M., Schofield R.S. Dilated cardiomyopathy and acute liver injury associated with combined use of ephedra, gamma-hydroxybutyrate, and anabolic steroids. Pharmacotherapy 2005, 25:756-761.
39. Cole J.C., Smith R., Halford J.C., Wagstaff G.F. A preliminary investigation into the relationship between anabolic-androgenic steroid use and the symptoms of reverse anorexia in both current and ex-users. Psychopharmacology (Berl) 2003, 166:424-429.
40. Conacher G.N., Workman D.G. Violent crime possibly associated with anabolic steroid use. Am. J. Psychiatry 1989, 146:679.
41. Cooper C.J., Noakes T.D. Psychiatric disturbances in users of anabolic steroids. S. Afr. Med. J. 1994, 84:509-512.
42. Cooper C.J., Noakes T.D., Dunne T., Lambert M.I., Rochford K. A high prevalence of abnormal personality traits in chronic users of anabolic-androgenic steroids. Br. J. Sports Med. 1996, 30:246-250.
43. Copeland J., Peters R., Dillon P. Anabolic-androgenic steroid use disorders among a sample of Australian competitive and recreational users. Drug Alcohol Depend. 2000, 60:91-96.
44. Crist D.M., Stackpole P.J., Peake G.T. Effects of androgenic-anabolic steroids on neuromuscular power and body composition. J. Appl. Physiol. 1983, 54:366-370.
45. D'Andrea A., Caso P., Salerno G., Scarafile R., De Corato G., Mita C., Di Salvo G., Severino S., Cuomo S., Liccardo B., Esposito N., Calabro R. Left ventricular early myocardial dysfunction after chronic misuse of anabolic androgenic steroids: a Doppler myocardial and strain imaging analysis. Br. J. Sports Med. 2007, 41:149-155.
46. Dalby J.T. Brief anabolic steroid use and sustained behavioral reaction. Am. J. Psychiatry 1992, 149:271-272.
47. Daly R.C. Anabolic steroids, brain and behaviour. Ir. Med. J. 2001, 94:102.
48. Daly R.C., Su T.P., Schmidt P.J., Pickar D., Murphy D.L., Rubinow D.R. Cerebrospinal fluid and behavioral changes after methyltestosterone administration: preliminary findings. Arch. Gen. Psychiatry 2001, 58:172-177.
49. Daly R.C., Su T.P., Schmidt P.J., Pagliaro M., Pickar D., Rubinow D.R. Neuroendocrine and behavioral effects of high-dose anabolic steroid administration in male normal volunteers. Psychoneuroendocrinology 2003, 28:317-331.
50. Danziger L., Schroeder H.T., Unger A. Androgen therapy for involutional melancholia. Arch. Neurol. Psychiatry 1944, 51:457-461.
51. David K., Dingemanse E., Freud J., Laquer E. Uber Krystallinisches mannliches Hormon Hoden (Testosteron), wirksamer als aus Harn oder aus Cholesterin Bereitetes Androsteron. Zeit. Physiol. Chem. 1935, 233:281-282.
52. Davidoff E., Goodstone G. Use of testosterone propionate in treatment of involutional psychosis in the male. Arch. Neurol. Psychiatry 1942, 48:811-817.
53. Dawson R. Drugs in sport - the role of the physician. J. Endocrinol. 2001, 170:55-61.
54. de la Torre Abril L., Ramada Benlloch F., Sanchez Ballester F., Ordono Dominguez F., Ulises Juan Escudero J., Navalon Verdejo P., Lopez Alcina E., Ramos de Campos M., Zaragoza Orts J. [Management of male sterility in patients taking anabolic steroids]. Arch. Esp. Urol. 2005, 58:241-244.
55. DeLeon K.R., Grimes J.M., Melloni R.H. Repeated anabolic-androgenic steroid treatment during adolescence increases vasopressin V(1A) receptor binding in Syrian hamsters: correlation with offensive aggression. Horm. Behav. 2002, 42:182-191.
56. Duchaine D. The Original Underground Steroid Handbook 1981, OEM Publishing, Santa Monica, CA.
57. Duchaine D. Underground Steroid Handbook 1983, OEM Publishing, Santa Monica, CA.
58. Duchaine D. Underground Steroid Handbook II 1988, HLR Technical Books, Los Angeles, CA.
59. DuRant R.H., Rickert V.I., Ashworth C.S., Newman C., Slavens G. Use of multiple drugs among adolescents who use anabolic steroids. N. Engl. J. Med. 1993, 328:922-926.
60. Elofson G., Elofson S. Steroids claimed our son's life. Phys. Sportsmed. 1990, 18:15-16.
61. Faigenbaum A.D., Zaichkowsky L.D., Gardner D.E., Micheli L.J. Anabolic steroid use by male and female middle school students. Pediatrics 1998, 101:E6.
62. Field A.E., Austin S.B., Camargo C.A., Taylor C.B., Striegel-Moore R.H., Loud K.J., Colditz G.A. Exposure to the mass media, body shape concerns, and use of supplements to improve weight and shape among male and female adolescents. Pediatrics 2005, 116:214-220.
63. Fischer S.G., Ricci L.A., Melloni R.H. Repeated anabolic/androgenic steroid exposure during adolescence alters phosphate-activated glutaminase and glutamate receptor 1 (GluR1) subunit immunoreactivity in Hamster brain: correlation with offensive aggression. Behav. Brain Res. 2007, 180:77-85.
64. Fitzpatrick F. Where steroids were all the rage: A doctor's curiosity and a businessman's love of weightlifting set off a revolution in York 2002, Philadelphia Inquirer, Philadelphia, PA.
65. Forbes G.B., Porta C.R., Herr B.E., Griggs R.C. Sequence of changes in body composition induced by testosterone and reversal of changes after drug is stopped. JAMA 1992, 267:397-399.
66. Freinhar J.P., Alvarez W. Androgen-induced hypomania. J. Clin. Psychiatry 1985, 46:354-355.
67. Friedl K.E., Jones R.E., Hannan C.J., Plymate S.R. The administration of pharmacological doses of testosterone or 19-nortestosterone to normal men is not associated with increased insulin secretion or impaired glucose tolerance. J. Clin. Endocrinol. Metab. 1989, 68:971-975.
68. Friedl K.E., Dettori J.R., Hannan C.J., Patience T.H., Plymate S.R. Comparison of the effects of high dose testosterone and 19-nortestosterone to a replacement dose of testosterone on strength and body composition in normal men. J. Steroid Biochem. Mol. Biol. 1991, 40:607-612.
69. Frye C.A. Some rewarding effects of androgens may be mediated by actions of its 5alpha-reduced metabolite 3alpha-androstanediol. Pharmacol. Biochem. Behav. 2007, 86:354-367.
70. Fudala P.J., Weinrieb R.M., Calarco J.S., Kampman K.M., Boardman C. An evaluation of anabolic-androgenic steroid abusers over a period of 1 year: seven case studies. Ann. Clin. Psychiatry 2003, 15:121-130.
71. Galduroz J.C., Noto A.R., Nappo S.A., Carlini E.A. Household survey on drug abuse in Brazil: study involving the 107 major cities of the country - 2001. Addict. Behav. 2005, 30:545-556.
72. Gallaway S. The Steroid Bible 1997, Belle International, Honolulu. Third Edition.
73. Glazer G. Atherogenic effects of anabolic steroids on serum lipid levels. A literature review. Arch. Intern. Med. 1991, 151:1925-1933.
74. Golding L., Freydinger J., Fishel S. Weight, size and strength - unchanged with steroids. Phys. Sportsmed. 1974, 2:39-43.
75. Gorayski P., Thompson C.H., Subhash H.S., Thomas A.C. Hepatocellular carcinoma associated with recreational anabolic steroid use. Br. J. Sports Med. 2008, 42:74-75. discussion 75.
76. Gottesman I.I., Gould T.D. The endophenotype concept in psychiatry: etymology and strategic intentions. Am. J. Psychiatry 2003, 160:636-645.
77. Gribetz D., Sweet A., Becker A., Levitt M., Hodes H. Use of anabolic steroids to reduce hypercalcemia and hypercalcuria caused by immobilization in paralytic poliomyelitis. AMA Am. J. Dis. Child. 1955, 90:612-613.
78. Gridley D.W., Hanrahan S.J. Anabolic-androgenic steroid use among male gymnasium participants: knowledge and motives. Sports Health 1994, 12:11-14.
79. Grimes J.M., Melloni R.H. Prolonged alterations in the serotonin neural system following the cessation of adolescent anabolic-androgenic steroid exposure in hamsters (Mesocricetus auratus). Behav. Neurosci. 2006, 120:1242-1251.
80. Grinspoon S., Corcoran C., Stanley T., Baaj A., Basgoz N., Klibanski A. Effects of hypogonadism and testosterone administration on depression indices in HIV-infected men. J. Clin. Endocrinol. Metab. 2000, 85:60-65.
81. Gruber A.J., Pope H.G. Psychiatric and medical effects of anabolic-androgenic steroid use in women. Psychother. Psychosom. 2000, 69:19-26.
82. Grundy S.M., Cleeman J.I., Merz C.N., Brewer H.B., Clark L.T., Hunninghake D.B., Pasternak R.C., Smith S.C., Stone N.J. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation 2004, 110:227-239.
83. Guirdham A. Treatment of mental disorders with male sex hormone. Br. Med. J. 1940, 1:10-12.
84. Hall R.C., Hall R.C., Chapman M.J. Psychiatric complications of anabolic steroid abuse. Psychosomatics 2005, 46:285-290.
85. Handelsman D.J., Gupta L. Prevalence and risk factors for anabolic-androgenic steroid abuse in Australian high school students. Int. J. Androl. 1997, 20:159-164.
86. Hannan C.J., Friedl K.E., Zold A., Kettler T.M., Plymate S.R. Psychological and serum homovanillic acid changes in men administered androgenic steroids. Psychoneuroendocrinology 1991, 16:335-343.
87. Hartgens F., Kuipers H. Effects of androgenic-anabolic steroids in athletes. Sports Med. 2004, 34:513-554.
88. Hartgens F., Rietjens G., Keizer H.A., Kuipers H., Wolffenbuttel B.H. Effects of androgenic-anabolic steroids on apolipoproteins and lipoprotein (a). Br. J. Sports Med. 2004, 38:253-259.
89. Haupt H.A., Rovere G.D. Anabolic steroids: a review of the literature. Am. J. Sports Med. 1984, 12:469-484.
90. Hays L.R., Littleton S., Stillner V. Anabolic steroid dependence. Am. J. Psychiatry. 1990, 147:122.
91. Henderson L.P. Steroid modulation of GABAA receptor-mediated transmission in the hypothalamus: effects on reproductive function. Neuropharmacology 2007, 52:1439-1453.
92. Hochberg Z., Pacak K., Chrousos G.P. Endocrine withdrawal syndromes. Endocr. Rev. 2003, 24:523-538.
93. Irving L.M., Wall M., Neumark-Sztainer D., Story M. Steroid use among adolescents: findings from Project EAT. J. Adolesc. Health 2002, 30:243-252.
94. Itil T.M., Michael S.T., Shapiro D.M., Itil K.Z. The effects of mesterolone, a male sex hormone in depressed patients (a double blind controlled study). Methods Find. Exp Clin. Pharmacol. 1984, 6:331-337.
95. Jin B., Turner L., Walters W.A., Handelsman D.J. The effects of chronic high dose androgen or estrogen treatment on the human prostate [corrected]. J. Clin. Endocrinol. Metab. 1996, 81:4290-4295.
96. Johansson P., Lindqvist A., Nyberg F., Fahlke C. Anabolic androgenic steroids affects alcohol intake, defensive behaviors and brain opioid peptides in the rat. Pharmacol. Biochem. Behav. 2000, 67:271-279.
97. Johnson M.D., Jay M.S., Shoup B., Rickert V.I. Anabolic steroid use by male adolescents. Pediatrics 1989, 83:921-924.
98. Johnston L.D., O'Malley P.M., Bachman J.G., Schulenberg J.E. Monitoring the future national survey results on drug use, 1975-2005. Volume II: College students and adults ages 19-45 (NIH Publication No. 06-5884). 2006, National Institute on Drug Abuse, Bethesda, MD.
99. Juhn M. Popular sports supplements and ergogenic aids. Sports Med. 2003, 33:921-939.
100. Kafrouni M.I., Anders R.A., Verma S. Hepatotoxicity associated with dietary supplements containing anabolic steroids. Clin. Gastroenterol. Hepatol. 2007, 5:809-812.
101. Kanayama G., Gruber A.J., Pope H.G., Borowiecki J.J., Hudson J.I. Over-the-counter drug use in gymnasiums: an underrecognized substance abuse problem?. Psychother. Psychosom. 2001, 70:137-140.
102. Kanayama G., Pope H.G., Hudson J.I. "Body image" drugs: a growing psychosomatic problem. Psychother. Psychosom. 2001, 70:61-65.
103. Kanayama G., Cohane G.H., Weiss R.D., Pope H.G. Past anabolic-androgenic steroid use among men admitted for substance abuse treatment: an underrecognized problem?. J. Clin. Psychiatry 2003, 64:156-160.
104. Kanayama G., Pope H.G., Cohane G., Hudson J.I. Risk factors for anabolic-androgenic steroid use among weightlifters: a case-control study. Drug Alcohol Depend. 2003, 71:77-86.
105. Kanayama G., Barry S., Hudson J.I., Pope H.G. Body image and attitudes toward male roles in anabolic-androgenic steroid users. Am. J. Psychiatry 2006, 163:697-703.
106. Kanayama G., Amiaz R., Seidman S., Pope H.G. Testosterone supplementation for depressed men: current research and suggested treatment guidelines. Exp. Clin. Psychopharmacol. 2007, 15:529-538.
107. Kanayama G., Boynes M., Hudson J.I., Field A.E., Pope H.G. Anabolic steroid abuse among teenage girls: An illusory problem?. Drug Alcohol Depend. 2007, 88:156-162. PMC 1978191.
108. Kanayama G., Brower K.J., Wood R.I., Hudson J.I., Pope H.G. Anabolic-androgenic steroid dependence: an emerging disorder. Addiction 2010, 104:1966-1978.
109. Kanayama G., Hudson J.I., Pope H.G. Long-term psychiatric and medical consequences of anabolic-androgenic steroid abuse: a looming public health concern?. Drug Alcohol Depend. 2008, 98:1-12.
110. Kanayama G., Brower K.J., Wood R.I., Hudson J.I., Pope H.G. Issues for DSM-V: clarifying the diagnostic criteria for anabolic-androgenic steroid dependence. Am. J. Psychiatry 2009, 166:642-645.
111. Kanayama G., Hudson J.I., Pope H.G. Features of men with anabolic-androgenic steroid dependence: a comparison with nondependent AAS users and with AAS nonusers. Drug Alcohol Depend. 2009, 102:130-137.
112. Kashkin K.B., Kleber H.D. Hooked on hormones? An anabolic steroid addiction hypothesis. JAMA 1989, 262:3166-3170.
113. Kasikcioglu E., Oflaz H., Umman B., Bugra Z. Androgenic anabolic steroids also impair right ventricular function. Int. J. Cardiol. 2009, 134:123-125.
114. Katz D.L., Pope H.G. Les effets contraires psychologiques et psychiatriques du dopage aux stéroïdes androgenes et anabolisants. 1989, Second International Athletic Foundation World Symposium on Doping in Sport, Monte Carlo.
115. Kindlundh A.M., Isacson D.G., Berglund L., Nyberg F. Factors associated with adolescent use of doping agents: anabolic-androgenic steroids. Addiction 1999, 94:543-553.
116. Kindlundh A.M., Hagekull B., Isacson D.G., Nyberg F. Adolescent use of anabolic-androgenic steroids and relations to self-reports of social, personality and health aspects. Eur. J. Public Health 2001, 11:322-328.
117. Kindlundh A.M., Rahman S., Lindblom J., Nyberg F. Increased dopamine transporter density in the male rat brain following chronic nandrolone decanoate administration. Neurosci. Lett. 2004, 356:131-134.
118. Klotz F., Garle M., Granath F., Thiblin I. Criminality among individuals testing positive for the presence of anabolic androgenic steroids. Arch. Gen. Psychiatry 2006, 63:1274-1279.
119. Kokkevi A., Fotiou A., Chileva A., Nociar A., Miller P. Daily exercise and anabolic steroids use in adolescents: a cross-national European study. Subst. Use Misuse 2008, 43:2053-2065.
120. Kopera H. The history of anabolic steroids and a review of clinical experience with anabolic steroids. Acta Endocrinol. Suppl. (Copenh) 1985, 271:11-18.
121. Kouri E.M., Pope H.G., Oliva P.S. Changes in lipoprotein-lipid levels in normal men following administration of increasing doses of testosterone cypionate. Clin. J. Sport Med. 1996, 6:152-157.
122. Krieg A., Scharhag J., Albers T., Kindermann W., Urhausen A. Cardiac tissue Doppler in steroid users. Int. J. Sports Med. 2007, 28:638-643.
123. Kuipers H., Hartgens F. [The use of drugs to improve athletic performance]. Ned. Tijdschr. Geneeskd. 1997, 141:1965-1968.
124. Kurling S., Kankaanpaa A., Ellermaa S., Karila T., Seppala T. The effect of sub-chronic nandrolone decanoate treatment on dopaminergic and serotonergic neuronal systems in the brains of rats. Brain Res. 2005, 1044:67-75.
125. Kurling S., Kankaanpaa A., Seppala T. Sub-chronic nandrolone treatment modifies neurochemical and behavioral effects of amphetamine and 3,4-methylenedioxymethamphetamine (MDMA) in rats. Behav. Brain Res. 2008, 189:191-201.
126. Larkin G.L. Carcinoma of the prostate. N. Engl. J. Med. 1991, 324:1892.
127. Lefavi R., Reeve T., Newland M. Relationship between anabolic steroid use and selected psychological parameters in male bodybuilders. J. Sport Behav. 1990, 13:157-166.
128. Leit R.A., Pope H.G., Gray J.J. Cultural expectations of muscularity in men: the evolution of Playgirl centerfolds. Int. J. Eat. Disord. 2001, 29:90-93.
129. Leit R.A., Gray J.J., Pope H.G. The media's representation of the ideal male body: a cause for muscle dysmorphia?. Int. J. Eat. Disord. 2002, 31:334-338.
130. Lenders J.W., Demacker P.N., Vos J.A., Jansen P.L., Hoitsma A.J., van 't Laar A., Thien T. Deleterious effects of anabolic steroids on serum lipoproteins, blood pressure, and liver function in amateur body builders. Int. J. Sports Med. 1988, 9:19-23.
131. Lindqvist A.S., Johansson-Steensland P., Nyberg F., Fahlke C. Anabolic androgenic steroid affects competitive behaviour, behavioural response to ethanol and brain serotonin levels. Behav. Brain Res. 2002, 133:21-29.
132. Llewellyn W. Anabolics 9th Edition. Molecular Nutrition 2009, Jupiter, Florida.
133. Malone D.A., Dimeff R.J. The use of fluoxetine in depression associated with anabolic steroid withdrawal: a case series. J. Clin. Psychiatry 1992, 53:130-132.
134. Malone D.A., Dimeff R.J., Lombardo J.A., Sample R.H. Psychiatric effects and psychoactive substance use in anabolic-androgenic steroid users. Clin. J. Sport Med. 1995, 5:25-31.
135. Maravelias C., Dona A., Stefanidou M., Spiliopoulou C. Adverse effects of anabolic steroids in athletes. A constant threat. Toxicol. Lett. 2005, 158:167-175.
136. Martorana G., Concetti S., Manferrari F., Creti S. Anabolic steroid abuse and renal cell carcinoma. J. Urol. 1999, 162:2089.
137. Matsumoto A.M. Effects of chronic testosterone administration in normal men: safety and efficacy of high dosage testosterone and parallel dose-dependent suppression of luteinizing hormone, follicle-stimulating hormone, and sperm production. J. Clin. Endocrinol. Metab. 1990, 70:282-287.
138. McBride A.J., Williamson K., Petersen T. Three cases of nalbuphine hydrochloride dependence associated with anabolic steroid use. Br. J. Sports Med. 1996, 30:69-70.
139. McCabe S.E., Brower K.J., West B.T., Nelson T.F., Wechsler H. Trends in non-medical use of anabolic steroids by U.S. college students: results from four national surveys. Drug Alcohol Depend. 2007, 90:243-251.
140. Melia P., Pipe A., Greenberg L. The use of anabolic-androgenic steroids by Canadian students. Clin. J. Sport Med. 1996, 6:9-14.
141. Melloni R.H., Connor D.F., Hang P.T., Harrison R.J., Ferris C.F. Anabolic-androgenic steroid exposure during adolescence and aggressive behavior in golden hamsters. Physiol. Behav. 1997, 61:359-364.
142. Menon D.K. Successful treatment of anabolic steroid-induced azoospermia with human chorionic gonadotropin and human menopausal gonadotropin. Fertil. Steril. 2003, 79(Suppl. 3):1659-1661.
143. Middleman A.B., Faulkner A.H., Woods E.R., Emans S.J., DuRant R.H. High-risk behaviors among high school students in Massachusetts who use anabolic steroids. Pediatrics 1995, 96:268-272.
144. Midgley S.J., Heather N., Davies J.B. Dependence-producing potential of anabolic-androgenic steroids. Addict. Res. 1999, 7:539-550.
145. Midgley S.J., Heather N., Davies J.B. Levels of aggression among a group of anabolic-androgenic steroid users. Med. Sci. Law 2001, 41:309-314.
146. Modlinski R., Fields K.B. The effect of anabolic steroids on the gastrointestinal system, kidneys, and adrenal glands. Curr. Sports Med. Rep. 2006, 5:104-109.
147. Morgentaler A. Testosterone and prostate cancer: an historical perspective on a modern myth. Eur. Urol. 2006, 50:935-939.
148. Morgentaler A. New concepts regarding the relationship of testosterone and prostate cancer. Future Oncol. 2007, 3:123-126.
149. Moss H., Panzak G., Tarter R. Personality, mood, and psychiatric symptoms among anabolic steroid users. Am. J. Addict. 1992, 1:315-324.
150. Nakao A., Sakagami K., Nakata Y., Komazawa K., Amimoto T., Nakashima K., Isozaki H., Takakura N., Tanaka N. Multiple hepatic adenomas caused by long-term administration of androgenic steroids for aplastic anemia in association with familial adenomatous polyposis. J. Gastroenterol. 2000, 35:557-562.
151. National Institutes on Drug Abuse, 2000. NIDA announces multimedia public education initiative aimed at reversing rise in use of anabolic steroids by teens. Available online at ; accessed September 6, 2009. http://www.drugabuse.gov/MedAdv/00/NR4-14.html.
152. Nilsson S., Baigi A., Marklund B., Fridlund B. The prevalence of the use of androgenic anabolic steroids by adolescents in a county of Sweden. Eur. J. Public Health 2001, 11:195-197.
153. Nottin S., Nguyen L.D., Terbah M., Obert P. Cardiovascular effects of androgenic anabolic steroids in male bodybuilders determined by tissue Doppler imaging. Am. J. Cardiol. 2006, 97:912-915.
154. O'Shea J., Winkler W. Biochemical and physical effects of an anabolic steroid in competitive swimmers and weightlifters. Nutr. Rep. Int. 1970, 2:351-362.
155. Olivardia R., Pope H.G., Hudson J.I. Muscle dysmorphia in male weightlifters: a case-control study. Am. J. Psychiatry 2000, 157:1291-1296.
156. One Hundred Eighth United States Congress, 2004. Anabolic Steroid Control Act of 2004. Available online at ; accessed September 6, 2009. http://www.theorator.com/bills108/s2195.html.
157. The Steroid Trafficking Act of 1990 1990, One Hundred First United States Congress, U.S. Government Printing Office, Washington.
158. Orengo C.A., Fullerton L., Kunik M.E. Safety and efficacy of testosterone gel 1% augmentation in depressed men with partial response to antidepressant therapy. J. Geriatr. Psychiatry Neurol. 2005, 18:20-24.
159. Pagonis T.A., Angelopoulos N.V., Koukoulis G.N., Hadjichristodoulou C.S. Psychiatric side effects induced by supraphysiological doses of combinations of anabolic steroids correlate to the severity of abuse. Eur. Psychiatry 2006, 21:551-562.
160. Pagonis T.A., Angelopoulos N.V., Koukoulis G.N., Hadjichristodoulou C.S., Toli P.N. Psychiatric and hostility factors related to use of anabolic steroids in monozygotic twins. Eur. Psychiatry 2006, 21:563-569.
161. Pallesen S., Josendal O., Johnsen B.H., Larsen S., Molde H. Anabolic steroid use in high school students. Subst. Use Misuse. 2006, 41:1705-1717.
162. Papazisis G., Kouvelas D., Mastrogianni A., Karastergiou A. Anabolic androgenic steroid abuse and mood disorder: a case report. Int. J. Neuropsychopharmacol. 2007, 10:291-293.
163. Parkinson A.B., Evans N.A. Anabolic androgenic steroids: a survey of 500 users. Med. Sci. Sports Exerc. 2006, 38:644-651.
164. Parrott A.C., Choi P.Y., Davies M. Anabolic steroid use by amateur athletes: effects upon psychological mood states. J. Sports Med. Phys. Fitness 1994, 34:292-298.
165. Parssinen M., Seppala T. Steroid use and long-term health risks in former athletes. Sports Med. 2002, 32:83-94.
166. Pavlatos A.M., Fultz O., Monberg M.J., Vootkur A., Pharmd Review of oxymetholone: a 17alpha-alkylated anabolic-androgenic steroid. Clin. Ther. 2001, 23:789-801. ; discussion 771.
167. Perry P.J., Andersen K.H., Yates W.R. Illicit anabolic steroid use in athletes. A case series analysis. Am. J. Sports Med. 1990, 18:422-428.
168. Perry P.J., Yates W.R., Williams R.D., Andersen A.E., MacIndoe J.H., Lund B.C., Holman T.L. Testosterone therapy in late-life major depression in males. J. Clin. Psychiatry 2002, 63:1096-1101.
169. Perry P.J., Kutscher E.C., Lund B.C., Yates W.R., Holman T.L., Demers L. Measures of aggression and mood changes in male weightlifters with and without androgenic anabolic steroid use. J. Forensic Sci. 2003, 48:646-651.
170. Perry P.J., Lund B.C., Deninger M.J., Kutscher E.C., Schneider J. Anabolic steroid use in weightlifters and bodybuilders: an internet survey of drug utilization. Clin. J. Sport Med. 2005, 15:326-330.
171. Peters K.D., Wood R.I. Androgen dependence in hamsters: overdose, tolerance, and potential opioidergic mechanisms. Neuroscience 2005, 130:971-981.
172. Petersson A., Garle M., Holmgren P., Druid H., Krantz P., Thiblin I. Toxicological findings and manner of death in autopsied users of anabolic androgenic steroids. Drug Alcohol Depend. 2006, 81:241-249.
173. Phillips W. Anabolic Reference Guide 1985, Golden, CO.
174. Phillips W. Anabolic Reference Update 1991, Mile High Publishing, Golden, CO.
175. Pope H.G., Katz D.L. Bodybuilder's psychosis. Lancet 1987, 1:863.
176. Pope H.G., Katz D.L. Affective and psychotic symptoms associated with anabolic steroid use. Am. J. Psychiatry 1988, 145:487-490.
177. Pope H.G., Katz D.L. Homicide and near-homicide by anabolic steroid users. J. Clin. Psychiatry 1990, 51:28-31.
178. Pope H.G., Katz D.L. Psychiatric and medical effects of anabolic-androgenic steroid use. A controlled study of 160 athletes. Arch. Gen. Psychiatry 1994, 51:375-382.
179. Pope H.G., Katz D.L. Psychiatric effects of exogenous anabolic-androgenic steroids. Psychoneuroendocrinology: The scientific basis of clinical practice 2003, 331-358. American Psychiatric Press, Washington, DC. O.M. Wolkowitz, A.J. Rothschild (Eds.).
180. Pope H., Brower K. Anabolic-Androgenic Steroid Abuse. Comprehensive Textbook of Psychiatry 2005, 1318-1328. Lippincott Williams and Wilkins, Philadelphia, PA. B. Sadock, V. Sadock (Eds.).
181. Pope H.G., Brower K.J. Anabolic-Androgenic Steroid-Related Disorders. Comprehensive Textbook of Psychiatry 2009, 1419-1431. Lippincott Williams and Wilkins, Philadelphia, PA. Ninth Edition. B. Sadock, V. Sadock (Eds.).
182. Pope H.G., Kouri E.M., Powell K.F., Campbell C., Katz D.L. Anabolic-androgenic steroid use among 133 prisoners. Compr. Psychiatry 1996, 37:322-327.
183. Pope H.G., Gruber A.J., Choi P., Olivardia R., Phillips K.A. Muscle dysmorphia. An underrecognized form of body dysmorphic disorder. Psychosomatics 1997, 38:548-557.
184. Pope H.G., Olivardia R., Gruber A., Borowiecki J. Evolving ideals of male body image as seen through action toys. Int. J. Eat. Disord. 1999, 26:65-72.
185. Pope H., Phillips K., Olivardia R. The Adonis complex: The secret crisis of male body obsession 2000, Simon and Schuster, New York.
186. Pope H.G., Kouri E.M., Hudson J.I. Effects of supraphysiologic doses of testosterone on mood and aggression in normal men: a randomized controlled trial. Arch. Gen. Psychiatry 2000, 57:133-140. discussion 155-6.
187. Pope H.G., Olivardia R., Borowiecki J.J., Cohane G.H. The growing commercial value of the male body: a longitudinal survey of advertising in women's magazines. Psychother. Psychosom. 2001, 70:189-192.
188. Pope H.G., Cohane G.H., Kanayama G., Siegel A.J., Hudson J.I. Testosterone gel supplementation for men with refractory depression: a randomized, placebo-controlled trial. Am. J. Psychiatry 2003, 160:105-111.
189. Pope H.G., Kanayama G., Ionescu-Pioggia M., Hudson J.I. Anabolic steroid users' attitudes towards physicians. Addiction 2004, 99:1189-1194.
190. Pope C.G., Pope H.G., Menard W., Fay C., Olivardia R., Phillips K.A. Clinical features of muscle dysmorphia among males with body dysmorphic disorder. Body Image 2005, 2:395-400.
191. Rabkin J.G., Wagner G.J., Rabkin R. A double-blind, placebo-controlled trial of testosterone therapy for HIV-positive men with hypogonadal symptoms. Arch. Gen. Psychiatry 2000, 57:141-147. discussion 155-6.
192. Rabkin J.G., Wagner G.J., McElhiney M.C., Rabkin R., Lin S.H. Testosterone versus fluoxetine for depression and fatigue in HIV/AIDS: a placebo-controlled trial. J. Clin. Psychopharmacol. 2004, 24:379-385.
193. Rachon D., Pokrywka L., Suchecka-Rachon K. Prevalence and risk factors of anabolic-androgenic steroids (AAS) abuse among adolescents and young adults in Poland. Soz. Praventivmed. 2006, 51:392-398.
194. Reyes-Fuentes A., Veldhuis J.D. Neuroendocrine physiology of the normal male gonadal axis. Endocrinol. Metab. Clin. North Am. 1993, 22:93-124.
195. Ricci L.A., Rasakham K., Grimes J.M., Melloni R.H. Serotonin-1A receptor activity and expression modulate adolescent anabolic/androgenic steroid-induced aggression in hamsters. Pharmacol. Biochem. Behav. 2006, 85:1-11.
196. Ricci L.A., Schwartzer J.J., Melloni R.H. Alterations in the anterior hypothalamic dopamine system in aggressive adolescent AAS-treated hamsters. Horm. Behav. 2009, 55:348-355.
197. Riem K., Hursey K. Using anabolic-androgenic steroids to enhance physique and performance: effects on moods and behavior. Clin. Psychol. Rev. 1995, 15:235-256.
198. Roberts J.T., Essenhigh D.M. Adenocarcinoma of prostate in 40-year-old body-builder. Lancet 1986, 2:742.
199. Roberts A., Clapp B. Anabolic Steroids: Ultimate Research Guide 2006, Anabolic Books, Montgomery, Texas.
200. Rubinow D.R., Schmidt P.J. Androgens, brain, and behavior. Am. J. Psychiatry 1996, 153:974-984.
201. Sanchez-Osorio M., Duarte-Rojo A., Martinez-Benitez B., Torre A., Uribe M. Anabolic-androgenic steroids and liver injury. Liver Int. 2008, 28:278-282.
202. Santora L.J., Marin J., Vangrow J., Minegar C., Robinson M., Mora J., Friede G. Coronary calcification in body builders using anabolic steroids. Prev. Cardiol. 2006, 9:198-201.
203. Schmidt P.J., Berlin K.L., Danaceau M.A., Neeren A., Haq N.A., Roca C.A., Rubinow D.R. The effects of pharmacologically induced hypogonadism on mood in healthy men. Arch. Gen. Psychiatry 2004, 61:997-1004.
204. Schroeder J.P., Packard M.G. Role of dopamine receptor subtypes in the acquisition of a testosterone conditioned place preference in rats. Neurosci. Lett. 2000, 2(282):17-20.
205. Schulte H.M., Hall M.J., Boyer M. Domestic violence associated with anabolic steroid abuse. Am. J. Psychiatry 1993, 150:348.
206. Schwartzer J.J., Ricci L.A., Melloni R.H. Adolescent anabolic-androgenic steroid exposure alters lateral anterior hypothalamic serotonin-2A receptors in aggressive male hamsters. Behav. Brain Res. 2009, 199:257-262.
207. Schwartzer J.J., Ricci L.A., Melloni R.H. Interactions between the dopaminergic and GABAergic neural systems in the lateral anterior hypothalamus of aggressive AAS-treated hamsters. Behav. Brain Res. 2009, 203:15-22.
208. Seidman S.N., Rabkin J.G. Testosterone replacement therapy for hypogonadal men with SSRI-refractory depression. J. Affect. Disord. 1998, 48:157-161.
209. Seidman S.N., Spatz E., Rizzo C., Roose S.P. Testosterone replacement therapy for hypogonadal men with major depressive disorder: a randomized, placebo-controlled clinical trial. J. Clin. Psychiatry 2001, 62:406-412.
210. Seidman S.N., Miyazaki M., Roose S.P. Intramuscular testosterone supplementation to selective serotonin reuptake inhibitor in treatment-resistant depressed men: randomized placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2005, 25:584-588.
211. Seidman S.N., Orr G., Raviv G., Levi R., Roose S.P., Kravitz E., Amiaz R., Weiser M. Effects of testosterone replacement in middle-aged men with dysthymia: a randomized, placebo-controlled clinical trial. J. Clin. Psychopharmacol. 2009, 29:216-221.
212. Socas L., Zumbado M., Perez-Luzardo O., Ramos A., Perez C., Hernandez J.R., Boada L.D. Hepatocellular adenomas associated with anabolic androgenic steroid abuse in bodybuilders: a report of two cases and a review of the literature. Br. J. Sports Med. 2005, e27:39.
213. Stanley A., Ward M. Anabolic steroids-the drugs that give and take away manhood. A case with an unusual physical sign. Med. Sci. Law 1994, 34:82-83.
214. Su T.P., Pagliaro M., Schmidt P.J., Pickar D., Wolkowitz O., Rubinow D.R. Neuropsychiatric effects of anabolic steroids in male normal volunteers. JAMA 1993, 269:2760-2764.
215. Talih F., Fattal O., Malone D. Anabolic steroid abuse: psychiatric and physical costs. Cleve. Clin. J. Med. 2007, 74:341-344. 346, 349-52.
216. Tamaki T., Shiraishi T., Takeda H., Matsumiya T., Roy R.R., Edgerton V.R. Nandrolone decanoate enhances hypothalamic biogenic amines in rats. Med. Sci. Sports Exerc. 2003, 35:32-38.
217. Tennant F., Black D.L., Voy R.O. Anabolic steroid dependence with opioid-type features. N. Engl. J. Med. 1988, 319:578.
218. Thiblin I., Parlklo T. Anabolic androgenic steroids and violence. Acta Psychiatr. Scand. Suppl. 2002, 125-128.
219. Thiblin I., Kristiansson M., Rajs J. Anabolic androgenic steroids and behavioural patterns among violent offenders. J. Forensic Psychiatr. 1997, 8:299-310.
220. Thiblin I., Finn A., Ross S.B., Stenfors C. Increased dopaminergic and 5-hydroxytryptaminergic activities in male rat brain following long-term treatment with anabolic androgenic steroids. Br. J. Pharmacol. 1999, 126:1301-1306.
221. Thiblin I., Runeson B., Rajs J. Anabolic androgenic steroids and suicide. Ann. Clin. Psychiatry 1999, 11:223-231.
222. Thiblin I., Lindquist O., Rajs J. Cause and manner of death among users of anabolic androgenic steroids. J. Forensic Sci. 2000, 45:16-23.
223. Thompson P.D., Cullinane E.M., Sady S.P., Chenevert C., Saritelli A.L., Sady M.A., Herbert P.N. Contrasting effects of testosterone and stanozolol on serum lipoprotein levels. JAMA 1989, 261:1165-1168.
224. Trenton A.J., Currier G.W. Behavioural manifestations of anabolic steroid use. CNS Drugs 2005, 19:571-595.
225. Tricker R., Casaburi R., Storer T.W., Clevenger B., Berman N., Shirazi A., Bhasin S. The effects of supraphysiological doses of testosterone on angry behavior in healthy eugonadal men-a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81:3754-3758.
226. Turek P.J., Williams R.H., Gilbaugh J.H., Lipshultz L.I. The reversibility of anabolic steroid-induced azoospermia. J. Urol. 1995, 153:1628-1630.
227. United States Drug Enforcement Administration, 2002, Code Title 21; Controlled Substances Act; Section 812, Schedules of Controlled Substances. Available online at ; accessed September 6, 2009. http://www.usdoj.gov/dea/pubs/csa/812.htm.
228. United States Drug Enforcement Administration, 2007. DEA announces largest steroid enforcement action in U.S. history. Available online at ; accessed September 6, 2009. http://www.usdoj.gov/dea/pubs/pressrel/pr092407.html.
229. van Breda E., Keizer H.A., Kuipers H., Wolffenbuttel B.H. Androgenic anabolic steroid use and severe hypothalamic-pituitary dysfunction: a case study. Int. J. Sports Med. 2003, 24:195-196.
230. Velazquez I., Alter B.P. Androgens and liver tumors: Fanconi's anemia and non-Fanconi's conditions. Am. J. Hematol. 2004, 77:257-267.
231. Verdejo-Garcia A., Lawrence A.J., Clark L. Impulsivity as a vulnerability marker for substance-use disorders: review of findings from high-risk research, problem gamblers and genetic association studies. Neurosci. Biobehav. Rev. 2008, 32:777-810.
232. Vogel W., Klaiber E., Broverman D. Roles of the gonadal steroid hormones in psychiatric depression in men and women. Prog. Neuropsychopharmacol. 1978, 2:487-503.
233. Vogel W., Klaiber E.L., Broverman D.M. A comparison of the antidepressant effects of a synthetic androgen (mesterolone) and amitriptyline in depressed men. J. Clin. Psychiatry 1985, 46:6-8.
234. Wade N. Anabolic steroids: doctors denounce them, but athletes aren't listening. Science 1972, 176:1399-1403.
235. Wang C., Alexander G., Berman N., Salehian B., Davidson T., McDonald V., Steiner B., Hull L., Callegari C., Swerdloff R.S. Testosterone replacement therapy improves mood in hypogonadal men - a clinical research center study. J. Clin. Endocrinol. Metab. 1996, 81:3578-3583.
236. Wang C., Swerdloff R.S., Iranmanesh A., Dobs A., Snyder P.J., Cunningham G., Matsumoto A.M., Weber T., Berman N. Transdermal testosterone gel improves sexual function, mood, muscle strength, and body composition parameters in hypogonadal men. J. Clin. Endocrinol. Metab. 2000, 85:2839-2853.
237. Wanjek B., Rosendahl J., Strauss B., Gabriel H.H. Doping, drugs and drug abuse among adolescents in the State of Thuringia (Germany): prevalence, knowledge and attitudes. Int. J. Sports Med. 2007, 28:346-353.
238. Weiner, R.B., Kanayama, G., Hudson, J.I., Hutter, A.M., Picard, M.H., Pope, H.G., Baggish, A.L., in press. Chronic anabolic-androgenic steroid use is associated with left ventricular systolic and diastolic dysfunction (Abstract). Circulation.
239. Wemyss-Holden S.A., Hamdy F.C., Hastie K.J. Steroid abuse in athletes, prostatic enlargement and bladder outflow obstruction - is there a relationship?. Br. J. Urol. 1994, 74:476-478.
240. Wettstein A. Uber die kunstliche Herstellung des Testikelhormons Testosteron. Schweiz Med. Wochenschr. 1935, 16:912.
241. Williamson D.J. Anabolic steroid use among students at a British college of technology. Br. J. Sports Med. 1993, 27:200-201.
242. Wilson-Fearon C., Parrott A.C. Multiple drug use and dietary restraint in a Mr. Universe competitor: psychobiological effects. Percept. Mot. Skills 1999, 88:579-580.
243. Wines J.D., Gruber A.J., Pope H.G., Lukas S.E. Nalbuphine hydrochloride dependence in anabolic steroid users. Am. J. Addict. 1999, 8:161-164.
244. Wood R.I. Reinforcing aspects of androgens. Physiol. Behav. 2004, 83:279-289.
245. Wood R.I. Anabolic steroids: a fatal attraction?. J. Neuroendocrinol. 2006, 18:227-228.
246. Wood R.I. Anabolic-androgenic steroid dependence? Insights from animals and humans. Front. Neuroendocrinol. 2008, 29:490-506.
247. Yang C.F., Gray P., Pope H.G. Male body image in Taiwan versus the West: Yanggang Zhiqi meets the Adonis complex. Am. J. Psychiatry 2005, 162:263-269.
248. Yang C.F., Gray P.B., Zhang J., Pope H.G. Second to fourth digit ratios, sex differences, and behavior in Chinese men and women. Soc. Neurosci. 2009, 4:49-59.
249. Yates W.R., Perry P., Murray S. Aggression and hostility in anabolic steroid users. Biol. Psychiatry 1992, 31:1232-1234.
250. Yates W.R., Perry P.J., MacIndoe J., Holman T., Ellingrod V. Psychosexual effects of three doses of testosterone cycling in normal men. Biol. Psychiatry 1999, 45:254-260.
251. Yesalis C.E., Kennedy N.J., Kopstein A.N., Bahrke M.S. Anabolic-androgenic steroid use in the United States. JAMA 1993, 270:1217-1221.
252. Yesalis C.E., Barsukiewicz C.K., Kopstein A.N., Bahrke M.S. Trends in anabolic-androgenic steroid use among adolescents. Arch. Pediatr. Adolesc. Med. 1997, 151:1197-1206.
253. Zeifert M. Massive dose testosterone therapy in male involutional psychosis. Psychiatr. Q. 1942, 16:319-332.